Dulaglutide and Liraglutide are the first-line peptide APIs we manufactured in 2022, and we have currently expanded our production capacity to a 5kg batch size. For industrial-scale quantities, Bachem would be the company to contact. We enable rapid project initiation across diverse domains, including small molecules such as heterocyclic compounds, carbohydrates, peptides, and oligonucleotides. Our state-of-the-art facilities, situated in Garland, are home to over 11 dedicated scientists who provide best-in-class research services to global biotech and pharmaceutical industries, accelerating concepts from concept to commercialization.